1180P Single-institution real-life experience of 177Lu-DOTATATE treatment in progressive, well differentiated GEPNETs

To evaluate toxicity and interim efficacy of 177Lu-DOTATATE treatment (PPRT) in patients with progressive well differentiated GEPNETs. We prospectively evaluated GEPNET patients treated at our Institution from April 2019 to April 2020. PRRT treatment was given as 4 separate infusions, 7.4 GBq each. To evaluate the interim response, CT or MRI were performed after the second PRRT administration. Side effects were assessed applying CTCAEv5.0...